Combined Treatment for Acromegaly With Long-Acting Somatostatin Analogs and Pegvisomant: Long-Term Safety for Up to 4.5 Years (Median 2.2 Years) of Follow-Up in 86 Patients
European Journal of Endocrinology - United Kingdom
doi 10.1530/eje-08-0843
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2009
Authors
Publisher
Bioscientifica